Biomatics Capital Partners, a fledgling venture capital (VC) firm based in Seattle, has announced the closure of its inaugural fund at $200 million.
The fund was actually quietly disclosed in a filing with the securities and exchange commission (SEC) back in November, but today marks its official closure.
The VC firm is led by Boris Nikolic and Julie Sunderland, who have previously invested in technology companies across the health care and life sciences spectrum. Prior to Biomatics, Sunderland headed up one of the investment arms of the Bill and Melinda Gates Foundation, while Nikolic previously served as chief advisor for science and technology to Bill Gates himself.
Biomatics plans to invest in “transformational innovation at the intersection of healthcare and technology,” according to a company statement, and will focus on early-stage investments.
“It’s our goal to seek out radically innovative solutions — the outliers,” Sunderland said. “By combining the best of science with sound investment practices, we are looking to create extraordinary financial value for our investors and a pathway to better patient outcomes.”
This latest fund comes just a few weeks after fellow U.S. VC firm Lux Capital announced a fresh $400 million fund with similar aspirations — Lux backs “contrarians and outsiders from science and tech” with a focus on cutting edge “high-risk” technology.
Biomatics has already made a number of investments, including an AI-powered medication platform called AiCure, data security health startup Blue Talon, and several others.
“Our health care ecosystem is at a tipping point,” said Nikolic. “In the next decade, breakthrough science and technology will fundamentally transform the practice of medicine and delivery of health care. Data will drive this transformation.”
Biomatics plans to invest in up to 20 Series A-level companies with its first fund, with initial investments ranging from $5 million to $10 million.
